Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis

Journal of the Neurological Sciences

Volumn 166, Issue 1, 1999, Pages 16-22

  Brex, P A ^a   Gomez Anson, B ^b   Parker, G J M ^a   Molyneux, P D ^a   Miszkiel, K A ^c   Barker, G J ^a   MacManus, D G ^a   Davie, C A ^a   Plant, G T ^c   Miller, D H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Clinically isolated syndromes; MRI; Multiple Sclerosis (MS); N Acetyl aspartate (NAA); Normal appearing white matter (NAWM); Spectroscopy

Indexed keywords

CHOLINE; CREATINE; CREATINE PHOSPHATE; INOSITOL; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NERVE LESION; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; WHITE MATTER;

EID: 0033563766     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(99)00105-7     Document Type: Article

References (36)

1. Miller D.H. Magnetic resonance in monitoring the treatment of multiple sclerosis. Ann Neurol. 36:1994;S91-S94.
2. Filippi M., Horsfield M.A., Tofts P.S., Barkhof F., Thompson A.J., Miller D.H. Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain. 118:1995;1601-1612.
3. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
4. Miller D.H., Austin S.J., Connelly A., Youl B.D., Gadian D.G., McDonald W.I. Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis. The Lancet. 337:1991;58-59. Letter.
5. Davie C.A., Hawkins C.P., Barker G.J., Brennan A., Tofts P.S., Miller D.H., et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis. Brain. 117:1994;49-58.
6. Arnold D.L., Riess G.T., Matthews P.M., Francis G.S., Collins D.L., Wolfson C., et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol. 36:1994;76-82.
7. Davie C.A., Barker G.J., Webb S., Tofts P.S., Thompson M., Harding A.E., et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxias is associated with axonal loss. Brain. 118:1995;1583-1592.
8. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry. 63:1997;736-742.
9. Arnold D.L., Matthews P.M., Francis G.S., O'Connor J., Antel J.P. Proton magnetic resonance spectroscopic imaging for metabolic characterisation of demyelinating plaques. Ann Neurol. 31:1992;235-241.
10. 1H spectroscopic imaging. Ann Neurol. 36:1994;157-165.
11. De Stefano N., Matthews P.M., Antel J., Preul M., Francis G., Arnold D.L. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol. 38:1995;901-909.
12. Narayana P.A., Doyle T.J., Lai D., Wolinsky J.S. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging and quantitative lesion volumetry in multiple sclerosis. Ann Neurol. 43:1998;56-71.
13. Fu L., Matthews P.M., De Stefano N., Worsley K.J., Narayanan S., Francis G.S., et al. Imaging axonal damage of normal appearing white matter in multiple sclerosis. Brain. 121:1998;103-113.
14. Allen I.V., McKeown S.R. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci. 41:1979;81-91.
15. Miller D.H., Johnson G., Tofts P.S., MacManus D., McDonald W.I. Precise relaxation time measurements of normal-appearing white matter in inflammatory central nervous system disease. Magn Reson Med. 11:1989;331-336.
16. Armspach J.P., Gounot D., Rumbach L., Chambron J. In vivo determination of multi- exponential T2 relaxation in the brain of patients with multiple sclerosis. Magn Res Imag. 9:1991;107-113.
17. Filippi M., Campi A., Dousset V., Baratti C., Martinelli V., Canal N., et al. A magnetisation transfer imaging study of normal appearing white matter in multiple sclerosis. Neurology. 45:1995;478-482.
18. Loevner L.A., Grossman R.I., Cohen J.A., Lexa F.J., Kessler D., Kolson D.L. Microscopic disease in normal-appearing white matter on conventional images in patients with multiple sclerosis: assessment with magnetization-transfer measurements. Radiology. 196:1995;511-515.
19. Gasperini C., Horsfield M.A., Thorpe J.W., Kidd D., Barker G.J., Tofts P.S., et al. Macroscopic and microscopic assessments of disease burden by MRI in multiple sclerosis: relationship to clinical parameters. J Magn Reson Imag. 6:1996;580-584.
20. 1H MIRSI of normal appearing white matter in multiple sclerosis. Multiple sclerosis. 3:1997;231-237.
21. Provencher S.W. Estimation of metabolite concentrations from localised in vivo proton NMR spectra. Mag Reson Med. 30:1993;672-679.
22. Simmons M.L., Frondoza C.G., Coyle J.T. Immunocytochemical localisation of N-acetyl aspartate with monoclonal antibodies. Neuroscience. 45:1991;37-45.
23. Urenjak J., Williams S.R., Gadian D.G., Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci. 13:1993;981-989.
24. Miller B.L., Moats R.A., Shonk T., Ernst T., Wooley S., Ross B.D. Alzheimer's disease: Depiction of increased myo-inositol with proton MR spectroscopy. Radiology. 187:1993;433-437.
25. 1H NMR spectroscopy. Neurology. 43:1993;2689-2695.
26. Davie C.A., Wenning G.K., Barker G.J., Tofts P.S., Kendall B.E., Quinn N., et al. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol. 37:1995;204-210.
27. O'Riordan J.I., Thompson A.J., Kingsley D.P., MacManus D.G., Kendall B.E., Rudge P., et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10 year follow-up. Brain. 121:1998;495-503.
28. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R.A., Mork S., Bo L. Axon transection in the lesions of multiple sclerosis. N Engl J Med. 338:1998;278-285.
29. Ferguson B., Matyszak M.K., Esiri M.M., Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain. 120:1997;393-399.
30. Macouillard F., Voison P., Merle M., Caniona P. Metabolic characterisation of microglial cells under a heat stress situation. Abstracts Soc Magn Reson. 3:1995;1726.
31. Brenner R.E., Munro P.M., Williams S.C., Bell J.D., Barker G.J., Hawkins C.P., et al. The proton NMR spectrum in acute EAE: significance of the change in the Cho:Cre ratio. Mag Reson Med. 29:1993;737-745.
32. Koopmans R.A., Li D.K., Zhu G., Allen P.S., Penn A., Paty D.W. Magnetic resonance spectroscopy of multiple sclerosis: in-vivo detection of myelin breakdown products. The Lancet. 341:1993;631-632.
33. Kermode A.G., Thompson A.J., Tofts P., MacManus D.G., Kendall B.E., Kingsley D.P., et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain. 113:1990;1477-1489.
34. Katz D., Taubenberger J.K., Cannella B., McFarlin D.E., Raine C.S., McFarland H.F. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol. 34:1993;661-669.
35. Thorpe J.W., Barker G.J., Jones S.J., Moseley I., Losseff N., MacManus D.G., et al. Magnetisation transfer ratios and transverse magnetisation decay curves in optic neuritis: correlation with clinical findings and electrophysiology. J Neurol Neurosurg Psychiatry. 59:1995;487-492.
36. Silver N.C., Barker G.J., MacManus D.G., Miller D.H., Thorpe J.W., Howard R.S. Decreased magnetisation transfer ratio due to demyelination: a case of central pontine myelinolysis. J Neurol Neurosurg Psychiatry. 61:1996;208-209.